MAS1L and acute respiratory distress syndrome: In view of the demonstrated general therapeutic potential of the Protective Arm of RAS in these organs and systems (Unger et al. 2015), treatment of severe ARDS in COVID-19 with AT2R and MasR agonists may concomitantly confer beneficial effects that reduce the overall end-organ damage of this disease.